Clinical trials: Chronic Obstructive Pulmonary
Chronic Fatigue Syndrome
Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome
Chronic fatigue syndrome is a disabling illness for which there is no specific treatment. As a group, CFS patients have disturbed sleep with frequent arousals and the sense of not having slept upon awakening.
- Trial name
- NCT00498485
- Testing
- Sodium Oxybate
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Inhaled Steroids on Gene Expression in the Lungs - 2
The purpose of this study is to assess the effect of inhaled beclomethasone (an inhaled corticosteroid) on the pattern of the lung airway epithelium and alveolar macrophages gene expression of healthy smokers.
- Trial name
- NCT00826748
- Testing
- Beclomethasone
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Chronic Obstructive Pulmonary Disease (COPD)
Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)
This is a multicenter, randomized, double-blind, parallel group, chronic-dosing (24 weeks), placebo-controlled study to assess the efficacy and safety of Glycopyrrolate (GP and Formoterol Fumarate (FF) combination metered-dose…
- Trial name
- NCT01854658
- Testing
- GFF MDI (PT003), GP MDI (PT001), FF MDI (PT005)
- Where
- 113 sites in United States
- Volunteers
- 1,615 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to compare the efficacy and safety/tolerability of indacaterol and glycopyrronium (QVA149) (fixed-dose combination) with fluticasone/salmeterol over a 26-week period in patients with moderate to…
- Trial name
- ILLUMINATE (NCT01315249)
- Testing
- indacaterol and glycopyrronium (QVA149), fluticasone/salmeterol
- Where
- 93 sites in Belgium, Czechia and 7 more
- Volunteers
- 523 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This study assessed the efficacy, safety and tolerability of the co-administration of NVA237 plus indacaterol taken once daily versus indacaterol taken once daily in patients with moderate to severe Chronic Obstructive Pulmonary…
- Trial name
- GLOW6 (NCT01604278)
- Testing
- NVA237 50 µg and indacaterol 150 µg
- Where
- 80 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 449 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, COPD
Reducing Dynamic Hyperinflation Through Breathing Retraining
This study will compare the effects of exercise training and breathing retraining (using metronome tones) to exercise training only. Exercise training lasts 12 weeks.
- Trial name
- NCT01009099
- Testing
- breathing retraining, exercise training
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- US Department of Veterans Affairs
Chronic Obstructive Pulmonary Disease
Osteopathy in Chronic Obstructive Pulmonary Disease (COPD) Rehabilitation Trial
The purpose of this trial is to verify if an osteopathic treatment added to usual pulmonary rehabilitation trial is able to improve the walking ability of COPD patients and if there is any influence on lung functionality.
- Trial name
- NCT00637299
- Testing
- Active osteopathic treatment (OMT+PR): Active Comparator
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Salvatore Maugeri
Pulmonary Disease, Chronic Obstructive
Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
The primary objective of the trial is to determine the 24-hour FEV1-time profile of tiotropium + olodaterol FDC, administered once daily by the RESPIMAT Inhaler after 6 weeks of treatment.
- Trial name
- NCT01559116
- Testing
- tiotropium + olodaterol, tiotropium, olodaterol
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 219 people
- Sponsor
- Boehringer Ingelheim
Kidney Transplantation, Kidney Disease
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
Alemtuzumab is a man-made antibody used to treat certain blood disorders. This study will evaluate treatment of kidney transplant recipients with alemtuzumab and other immune system suppressing medications with or without…
- Conditions
- Kidney Transplantation, Kidney Disease, Kidney Failure
- Trial name
- NCT00183248
- Testing
- Alemtuzumab, Mycophenolate mofetil, Sirolimus
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Miami
Medication Overuse Headache
Medication-overuse Headache: 4 Years Follow up
From 1 January 2004 to 31 December 2006 64 individuals with probable medication overuse headache were included in a randomized, 1-year open-labeled, multicentre study to evaluate the effect of early introduction of prophylactic…
- Trial name
- MOHfollowup (NCT00918671)
- Testing
- No new specific intervention
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- Norwegian University of Science and Technology
Chronic Low Back Pain
Placebo In Chronic Back Pain (Phase 2)
This study is designed to examine brain properties for placebo response in chronic back pain patients. The investigators have preliminary data indicating that, in blinded clinical trial studies with neutral instructions regarding…
- Trial name
- PICP2 (NCT02986334)
- Testing
- Naproxen, Omeprazole
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Apkar Apkarian
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
This is a 12-week (with an extension to 52 weeks in a subset of participants) study comparing the safety of BGF MDI HFO twice daily (BID) with BGF MDI HFA BID in participants with moderate to very severe COPD.
- Trial name
- NCT05573464
- Testing
- BGF MDI HFO 320/14.4/9.6 μg, BGF MDI HFA 320/14.4/9.6 μg
- Where
- 91 sites in United States, Argentina and 7 more
- Volunteers
- 559 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study was intended to assess how well inhaled NVA237 opens up the airways of patients with mild, moderate or severe COPD over a 24 hour period after a 14 day treatment period.
- Trial name
- NCT00856193
- Testing
- NVA237
- Where
- 2 sites in United States, Germany
- Volunteers
- 33 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
This study evaluates the safety of medicine on COPD (Chronic Obstructive Pulmonary Disease). This study will last up to 56 weeks, and subjects will visit the clinic 16 times.
- Trial name
- NCT00269087
- Testing
- fluticasone propionate/salmeterol combination DISKUS
- Where
- 5 sites in Japan
- Volunteers
- 122 people
- Sponsor
- GlaxoSmithKline
COPD
Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD
Study purpose is to evaluate if subjects with chronic obstructive pulmonary disease (COPD) are more likely to be responsive to additional inhaled corticosteroids if they have a positive response to hyperosmolar challenge with…
- Trial name
- NCT00860938
- Testing
- Budesonide
- Where
- Switzerland
- Volunteers
- 90 people
- Sponsor
- Cantonal Hospital, Baselland
Pulmonary Disease, Chronic Obstructive, Cigarette Smoking
E-Visit for COPD and Smoking Cessation
The goal of this work is to develop, refine, and pilot test an electronic visit (e-visit) to: 1) deliver smoking cessation treatment to adults at risk for COPD and 2) to improve rates of COPD early detection and accurate…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Cigarette Smoking, Telemedicine
- Trial name
- NCT04155073
- Testing
- smoking cessation, early COPD detection, electronic visit, Treatment As Usual
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Medical University of South Carolina
Sleep Apnea, Obstructive, Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease
The primary purpose of the study is to determine whether lemborexant increases the apnea hypopnea index (AHI) on Day 8 of treatment in adult and elderly participants (adults greater than or equal to [>=] 45 to less than [<] 65…
- Conditions
- Sleep Apnea, Obstructive, Pulmonary Disease, Chronic Obstructive, Respiration Disorders
- Trial name
- NCT04647383
- Testing
- Lemborexant 10 mg
- Where
- 11 sites in United States
- Volunteers
- 63 people
- Sponsor
- Eisai Inc.
Chronic Obstructive Pulmonary Disease
Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study was designed to obtain data about the efficacy and safety of 3 doses of indacaterol (150, 300, and 600 µg) in Japanese patients with chronic obstructive pulmonary disease (COPD) so that optimal dose(s) could be chosen…
- Trial name
- NCT00403845
- Testing
- Indacaterol 150 μg, Indacaterol 300 μg
- Where
- 8 sites in Japan
- Volunteers
- 50 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease, Asthma
Pre/Post Pilot Test of Video Module Education
Asthma and Chronic obstructive pulmonary disease (COPD) results in over a million hospitalizations in the United States annually and COPD is the third leading cause of 30-day re-hospitalizations.
- Trial name
- NCT02278237
- Testing
- VME Group
- Volunteers
- 90 people
- Sponsor
- University of Chicago
Asthma
Chronic Asthma Study in 2- to 5-Year-Old Patients (MK0476-072 )
A study in 2-5 year old children to evaluate the safety and tolerability of montelukast and placebo administered once daily at bed time.
- Trial name
- NCT00968201
- Testing
- montelukast sodium
- Volunteers
- 689 people
- Sponsor
- Organon and Co
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.